Sodium-glucose cotransporter type 2 (SGLT2) inhibitors should be considered for use in most patients with type 2 diabetes regardless of presence of atherosclerotic cardiovascular disease or history of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results